![Agonistic properties of ERα.\
**A.** Localization of the P~295~-T~311~ sequence within ERα. **B.** MCF-7 cell proliferation. Cells were grown in the absence (control) or presence of ERα17p at 10 μM or E~2~ at 0.1 nM taken as a reference. Cell growth was measured by crystal violet staining. **C.** ERE-dependent transcription. MVLN cells (MCF-7 cells stably transfected with a pVit-tk-Luc reporter plasmid (Pons et al., 1990) were incubated in the absence (control) or presence of ERα17p at 10 μM or E~2~ at 0.1 nM. Luciferase activity, assayed by luminometry, was normalized according to protein concentration in cell extracts. **D.** ERα level. MCF-7 cells were cultured in the absence (control) or presence of ERα17p at 1 and 10 μM or E~2~ at 0.1 nM. ERα and actin levels in cell extracts were determined by Western blot analysis. **E.** ERα degradation rate. \[^35^S\]methionine labeled MCF-7 cells were maintained in culture without (control) or with ERα17p at 10 μM or E~2~ at 1 nM. Immunoprecipitated \[^35^S\]ERα was submitted to SDS-PAGE, revealed by autofluorography and quantified by measuring band intensities. **F.** ERα mRNA level. MCF-7 cells were incubated in the absence (control) or presence of ERα17p at 10 μM or E~2~ at 0.1 nM. ERα mRNA levels were measured by NASBA (Nucleic Acid Sequence Based Amplification; (Compton, 1991; Verjat et al., 2004) and normalized according to PPIB mRNA levels. Figures A, B, C and D were adapted from (Gallo et al., 2007a) (Mol Cell Endocrinol 268, 37-49), figures E and F from (Gallo et al., 2008) (J Steroid Biochem Mol Biol, doi:10.1016/j.jsbmb.2007.12.012).](nrs06007.f1){#fig1}

![Sequence alignment of AR, ERRβ and ERRγ with ERα.\
**A.** AR E~621~-G~643~ versus ERα P~295~-T~311~. The AR inhibitory motif (R~629~KLKKLGN~636~) delineated by Haelens et al. (Haelens et al., 2007) is boxed. **B.** Orphan receptors ERRβ (C~158~-A~315~) and ERRγ (C~183~-A~340~) versus ERα (C~240~-E~419~), gaps within the orphan receptor regions corresponding to the C-terminus part of the ERα P~295~-T~311~ sequence are boxed. Sequences were downloaded from the ExPASy Proteomics Server (http://au.expasy.org) (accession numbers: ERα: P03372, AR: P10275, ERRβ: O95718 and ERRγ: P62508). Alignments were carried out using T-Coffee server (http://tcoffee.vital-it.ch) (Notredame et al., 2000). Hyphens (-) indicate a one-residue gap, stars (\*) notify identical amino acids, colons (:) and full points (.) highlight amino acids that belong to a 'strong' and a 'weak' group, respectively.](nrs06007.f2){#fig2}

![Induction of ERα activation/degradation cycles by putative peptides generated by the proteasomal degradation of ERα.\
In the absence of hormone, ERα-induced gene transcription is maintained at basal level by a low production of peptides originating from receptor proteasomal degradation. Agonists enhance the production of such peptides, giving rise to sustained ERα activation/degradation cycles. This enhancing signal would persist until receptor mRNA depletion.](nrs06007.f3){#fig3}

Introduction
============

Estrogen receptor α (ERα) is commonly depicted as a transcription factor which, once bound to the appropriate hormone (e.g., 17β-estradiol; E~2~), alters the expression of target genes. However, in view of discoveries made over the last decade, this simplistic concept must be reconsidered since the transcription of estrogen-regulated genes is actually a transient and cyclic mechanism involving successive recruitments and dissociations of a large number of corepressors and coactivators (see \[[@r47]\] for review). These coregulators, which modulate ERα activity to the same extent as cognate ligands, should not be viewed as *\"accessory proteins\"*, but rather as products of particular genes, historically called *\"master genes\"* \[[@r6]; [@r54]\], that orchestrate coherent and synchronized events (see \[[@r37]\] for review). According to this view, the search for drugs able to specifically interfere with coregulator recruitment may open new therapeutic avenues for the treatment of ERα-related diseases \[[@r19]; [@r24]; [@r38]; [@r52]; [@r62]\]. In order to design such compounds, one must have a clear understanding of the molecular mechanisms underlying the formation of active ERα oligomeric structures.

In this Perspective, we describe the regulatory function of the ERα P~295~-T~311~ amino-acid sequence, which harbors a binding site for calmodulin (CaM) \[[@r20]\], a coregulator playing a role of major importance in the ERα mechanism of action (see \[[@r43]\] for review). In addition, we propose that ERα degradation product(s), including the P~295~-T~311~ sequence, may contribute to the activation process of the receptor.

Link between proliferation and ERα downregulation
=================================================

Although involvement of ERα in the growth of hormone-dependent breast cancers has been clearly established, ERα expression in primary breast cancers is generally associated with a favorable prognosis, as compared to the ERα-negative phenotype. It is noteworthy that high amounts of ERα are correlated with a low expression of proliferation markers \[[@r31]\], clearly indicating an inverse relationship between receptor level and cell proliferation.

An inverse correlation between ERα stability and ERE-dependent gene expression has also been reported, leading to the widely held - albeit subject to controversy \[[@r1]; [@r7]; [@r15]; [@r16]\] - concept that the ubiquitin proteasome system (UPS) contributes to ERα-mediated gene transcription \[[@r36]; [@r45]; [@r60]\].

The ERα P~295~-T~311~ sequence is a regulatory platform
=======================================================

The P~295~-T~311~ sequence, located between the D- (hinge) and E- (**L**igand **B**inding **D**omain; LBD) domains, appears to be involved in both the stability and the transcriptional activity of the receptor. This short sequence, actually situated in the AF-2a (autonomous activation function) domain \[[@r51]; [@r58]\], can be considered as a platform for various posttranslational modifications such as phosphorylation \[[@r39]; [@r70]\], acetylation \[[@r69]\], SUMOylation \[[@r65]\] and monoubiquitination \[[@r13]; [@r28]\]. This motif also contains the third nuclear localization signal of the receptor \[[@r56]; [@r71]\], as well as a proteolysis site \[[@r64]\]. Finally, as stated above, the P~295~-T~311~ sequence includes a binding site for CaM \[[@r5]; [@r8]; [@r20]; [@r23]; [@r41]\], a coregulator which enhances both the transactivation \[[@r2]; [@r23]; [@r42]; [@r41]\] and the stabilization of the receptor \[[@r8]; [@r44]\] by impeding its E6-AP- (**E6-A**ssociated **P**rotein) mediated polyubiquitination \[[@r40]\]. It is obvious that these dual effects do not fit with the concept of a relationship between ERα-induced transcription and receptor proteolysis.

In order to further elucidate the role of the P~295~-T~311~ segment, we have synthesized a peptide with the same sequence: ERα17p (P~295~LMIKRSKKNSLALSLT~311~). Surprisingly, this peptide elicits estrogenic responses in ERα-expressing breast carcinoma cells \[[@r22]; [@r20]; [@r21]\]. Thus, ERα17p stimulates both cell proliferation and ERE-dependent transcription. This is associated with receptor downregulation, occurring through an increase of ERα degradation rate and a decrease of ERα mRNA level ([Figure 1](#fig1){ref-type="fig"}). Interestingly, it should be stressed that the latter response is typical of that elicited by agonist ligands. In spite of the fact that ERα17p binds to CaM and inhibits its association with ERα, its estrogenic action cannot be totally ascribed to a CaM-dependent mechanism since two ERα17p analogs, unable to associate with CaM, displayed estrogenic properties with a slightly higher efficiency \[[@r20]\].

The mechanism by which ERα17p and its analogs operate is not established as yet, although their intracellular penetration seems to be required (see below). In this regard, it should be stressed that ERα, like other nuclear hormone receptors, is subject to a constant trafficking between various intracellular compartments and targets, especially in the absence of (anti)estrogenic stimulation \[[@r35]; [@r37]; [@r46]; [@r57]; [@r66]\]. Hence, we may logically propose that our peptides may interfere with this process, as described for conventional ligands. Note, however, in this context we do not know if a particular or all forms of ERα (nuclear, cytoplasmic, membrane-associated, posttranslationally modified, etc.) are implicated in the mode of action of ERα17p.

Molecular mechanisms leading to ERα17p-induced estrogenic effects
=================================================================

Recent investigations from our laboratory have revealed that ERα17p binds to purified recombinant human ERα \[[@r21]\], most likely disrupting intramolecular interactions suspected to confer upon the receptor an inactive conformation (i.e., association between the S~305~-T~311~ sequence and the β-turn/H4 composite motif \[[@r30]\]). The additional finding that, in MCF-7 cells, ERα17p dissociates by competition with ERα-Hsp70 complexes \[[@r22]\], suggests a complementary mechanism that may contribute to the agonistic property of the peptide. According to these observations, we assume that the inactive, chaperone-stabilized, unliganded ERα adopts a structure where the hinge region is \"closed\" by an Hsp70-stabilized intramolecular interaction between the S~305~-T~311~ sequence and the β-turn/H4 motif. Agonist-induced Hsp dissociation destabilizes this inactive folding, provoking the \"opening\" of the hinge with a concomitant exposure of the P~295~-T~311~ motif. CaM, by associating with this motif, would stabilize the activated ERα oligomeric structure. This proposal, which of course requires further experimental validation, could be extended to other coregulators which modulate molecular interactions involving the P~295~-T~311~ sequence.

Hence, ERα17p and its analogs, regardless of their ability to interact with CaM, would activate ERα by relieving an auto-inhibitory folding and provoking concomitantly the dissociation of Hsp70. Likewise, we assume that CaM would produce a similar conformational change, accounting for the antiestrogenic activity of CaM antagonists.

The ERα P~295~-T~311~ motif has a repressive function
=====================================================

The model outlined above postulates the existence of an autoinhibitory function associated with the ERα P~295~-T~311~ sequence. In support to this view, we and others have observed that partial or complete deletion of the P~295~-T~311~ sequence leads to receptor mutants characterized by a constitutively high level of transcriptional activity \[[@r20]; [@r41]\]. Even in the absence of E~2~, these mutated receptors appear unstable, most likely because of rapid degradation. This could be explained by their potential inability to establish association with Hsp70. Interestingly, a motif with a repressive activity has also been recently localized in the hinge region of the human androgen receptor (AR) (i.e., R~629~KLKKLGN~636~ sequence; [Figure 2](#fig2){ref-type="fig"}A) \[[@r26]\], suggesting that other nuclear receptors may be subject to such autoregulation.

Genetic arguments support this concept of ERα autoinhibition. Indeed, a missense point mutation resulting in a K303R substitution was shown by Fuqua et al. to increase the sensitivity of the receptor to E~2~ \[[@r18]; [@r29]\]. This functional ERα alteration, which could be explained by a decrease of the autoinhibition exerted by the P~295~-T~311~ sequence, has been found associated with high tumor grade \[[@r11]\]. On the other hand, according to sequence alignments ([Figure 2](#fig2){ref-type="fig"}B), orphan estrogen receptors (**E**strogen receptor-**R**elated **R**eceptors; especially ERRβ and γ display a gap in the region corresponding to the ERα P~295~-T~311~ sequence, a characteristic which might explain the constitutive activity of these receptors.

Hence, one could speculate that drugs which enhance the repressive action of the P~295~-T~311~ sequence may be of therapeutic interest for the treatment of ERα-related diseases, especially in cases of antiestrogen resistance.

Is an endogenous production of ERα17p-like peptides conceivable?
================================================================

Direct interaction of a ligand with ERα is not an absolute prerequisite for its proteasomal degradation, as demonstrated with cells labeled with \[^3^H\] tamoxifen aziridine (\[^3^H\]TAZ), a partial antiestrogen which reacts covalently with the hormone binding pocket of ERα (Cys 530) \[[@r27]; [@r61]\], blocking access of other ligands \[[@r3]; [@r4]; [@r33]\]. Thus, in MCF-7 cells, accumulated ERα covalently liganded with \[^3^H\]TAZ vanishes upon treatment with conventional ligands, a property explained by the fact that ligand binding to newly synthesized receptors generates a signal appropriate for inducing \[^3^H\]TAZ-ERα degradation \[[@r4]\]. Similarly, a small percentage of ligand-bound receptor generates a response which also affects unliganded receptors, since very low amounts of E~2~ (sub-Kd doses) or short E~2~ pulses are sufficient to produce optimal transactivation, as well as the degradation of the whole receptor pool \[[@r14]; [@r25]; [@r55]\]. In fact, such behavior suggests the existence of (a) molecular signal(s) able to amplify the cellular response to hormonal stimulation. Could (a) peptide(s) derived from the hormone-induced proteasomal processing of ERα constitute such (a) signal(s), the \"missing link\" connecting receptor degradation and transactivation?

In view of the estrogenic activity of ERα17p, one may reasonably wonder whether there is a physiological, proteasome-mediated production of peptide(s) with similar estrogenic properties. Insofar as ERα-dependent transcription is impeded by inhibitors of proteasome \[[@r36]; [@r45]; [@r60]\], it seems logical to surmise that ERα breakdown which accompanies transactivation generates peptide(s) that, like ERα17p, could be involved in the receptor activation process ([Figure 3](#fig3){ref-type="fig"}). From a general point of view, one may propose that the UPS not only eliminates misfolded, damaged or obsolete proteins, but also generates signaling peptides.

If our hypothesis is correct, pure antiestrogens such as fulvestrant would not induce the emergence of such peptide(s) with stimulatory properties. The observation that the binding of pure antiestrogen causes the receptor to be processed by other UPS components - as compared to agonist binding - supports this view. Estrogen- and pure antiestrogen-induced proteasomal degradation indeed occur in different cellular compartments: while the first takes place in the cytosol, the latter implies a nuclear proteasome system \[[@r7]; [@r50]\], suggesting that agonists and antagonists may generate dissimilar ERα proteolytic profiles. In this regard, it should be stressed that several ways have been described by which ERα is polyubiquitinated and thus tagged for proteasomal degradation. While CHIP (**C**arboxyl **T**erminus of **H**sp70-**I**nteracting **P**rotein) exclusively polyubiquitinates unliganded ERα \[[@r17]; [@r67]\], MDM2 (**M**urine **D**ouble **M**inute **2**) seems to promote both basal and E~2~-associated ERα degradation \[[@r12]; [@r63]\]. By contrast, EFP (**E**strogen-responsive **F**inger **P**rotein) and E6-AP ubiquitin ligases seem to be good candidates for the specific processing of agonist-bound receptor \[[@r34]; [@r40]; [@r48]; [@r49]\].

In summary, we assume that agonist-induced proteasomal degradation of ERα may generate a positive feedback loop involving receptor degradation product(s). In this context, the UPS would not only contribute to promoter clearance, a step required for initiation and progression of new transcription cycles \[[@r45]; [@r60]\], but also enhance ERα activation. Even if our hypothesis is only based on indirect evidence, such a mechanism of response amplification is not unheard of. Indeed, a peptide (receptorphin) corresponding to a transmembrane segment of the opioid receptors has been reported to activate the latter \[[@r32]\]. Interestingly, these receptors are, like ERα, subjected to proteasomal degradation under agonist stimulation \[[@r9]\]. Hence, our hypothesis could apply not only to ERα and/or other nuclear receptors, but also to a number of UPS-targeted proteins. Assessment of function and fate of proteasome-processed peptides would provide important information in this regard.

Perspectives
============

In order to test our hypothesis, we are currently trying to decipher the peptidome of MCF-7 cells under various experimental conditions (e.g., treatment with agonists or pure antiestrogens). To date, studies carried out by using a classical LC-MS/MS approach have failed to reveal the presence of ERα17p-like peptides. Such a methodology, commonly used for detection of easily ionizable peptides in relatively high amounts, seems to be inappropriate in our case (hypothetical non-tryptic peptides in low concentrations). To alleviate this drawback, we have considered using N-terminal sulfonation because it facilitates the sequencing of newly formed peptides by predominantly inducing the formation of y-type ion series during MS/MS fragmentation. Derivatized peptides will be separated before analysis by liquid chromatography, and different ionization/detection methods such as MALDI-TOF/TOF or ESI-Orbitrap will be used. Alternatively, affinity chromatography on CaM- or Hsp70-immobilized matrices could be used to concentrate peptides of interest from cell extracts and conditioned culture media. Finally, peptide detection and/or extraction will also be performed using immunological approaches.

Our hypothesis, if confirmed, brings forth new perspectives in the ever-evolving field of cell signaling. In addition, clinical consequences would be considerable with regard to both diagnosis and therapy. From a diagnostic point of view, one may indeed speculate that in estrogen-related diseases such as breast cancers, these putative peptides would be overexpressed and perhaps secreted or displayed in association with the MHC (**M**ajor **H**istocompatibility **C**omplex). In a therapeutic context, one may conceive the design of specific inhibitors or anticipate immunotherapeutic strategies.
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